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I.

Introduction
Direct-to-Consumer (“DTC”) genetic testing raises a set of concerns involving inadequate

safeguards of test results to protect against the potential negative impact on personal privacy. The
concerns arise from insufficient federal and state laws. In a technology-driven society, the prospect
of data breaches releasing highly sensitive genetic information requires greater governmental
oversight. This article explores the question of whether DTC genetic testing, specifically testing
companies, should be subject to privacy requirements. An assessment of this issue requires first,
an explanation of DNA testing technology, second, an analysis of the current privacy frameworks
applicable to genetic testing, third, an assessment of the gaps in these frameworks, and last,
consideration of mechanisms to maintain individual autonomy and privacy.
II.

DNA Testing Technology
A “genetic test” is defined as “an analysis of human DNA, RNA, chromosomes, proteins,

or metabolites that detects genotypes, mutations, or chromosomal changes.”1 The evaluation of
DNA testing technology begins with a brief description of the molecular analysis techniques
followed by an in-depth analysis of DTC genetic tests (“DTC-GT”) and genetic testing companies.

1

74 Fed. Reg. 51701.
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A. Science of Genetic Testing
Genetic testing may be useful for determining paternity, matching forensic tissue, assessing
ancestry, and identifying genetic predispositions to specific diseases or reproductive risks. DTC
tests designed to identify genealogy or predisposition to disease are done by molecular techniques
such as polymerase chain reaction (“PCR”), and next-generation sequencing (either whole-exome
or whole-genome sequencing).2
1. The DNA Molecule
The Human Genome Project, started by the National Institute of Health (“NIH”) in 1990,
was designed to “decipher the massive amount of information contained in our genome – the DNA
(deoxyribonucleic acid) found within all our chromosomes.”3 DNA is the molecule of life that
makes up the chemical subunits of human chromosomes.4 A gene is the unit of heredity passed
from parent to offspring that affects traits/characteristics of an individual.5 The primary purpose
of DNA is to encode the information necessary in proteins for cell structure and function.6 A cell
synthesizes the proteins by a process known as gene expression in which a gene sequence affects
the characteristics of the cell.7 An individual’s gene sequence leads to the expression of
morphological, physiological, and behavioral traits.8 An alternate version of a specific gene known
as an allele can account for the differences in traits as each allele encodes a particular protein

2

ROBERT J. BROOKER, GENETICS ANALYSIS & PRINCIPLES 616 (5th ed. 2015). [hereinafter Genetic
Analysis].
3
Id. at 1.
4
Id. at 2.
5
Id. at 4.
6
Id. at 5.
7
Id. at 6.
8
Id. at 6-7.
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function or expression.9 These inherited differences in characteristics due to genetic variation10
make genetic tests useful.
2. Polymerase Chain Reaction (“PCR”) Testing
Molecular markers11 are useful in polymerase chain reactions and gel electrophoresis.12
PCR amplifies the gene from a sample of cells by separating the DNA strands with high
temperature leaving two free single-stranded DNA molecules.13 As the temperature lowers,
primers made of short single-stranded DNA bind to specific sites in the template DNA, each
binding near one end of the gene of interest.14 Once the primers bind, the temperature is raised
slightly, and a polymerase enzyme is added to the reaction to synthesize a strand of DNA
complementary to the single-stranded template DNA.15 The third step, known as primer extension
results in double the amount of template DNA.16 The three-step process of PCR can be repeated
for as many cycles as necessary. A typical PCR run can take a couple of hours.17
Once the template DNA sequence has been amplified, it may be tested for the presence of
the sequence by running either (1) the sample on a gel stained with ethidium bromide and
observing if the gel fluoresces under UV light or (2) with real-time PCR.18 Scientists can determine
the amount of the specific product as the PCR runs by adding a probe that emits fluorescence at a
particular wavelength.19 If a fluorescent band of the correct size or the level of the fluorescence

9

Id. at 7.
Id. at 186.
11
A molecular marker is a segment of DNA at a specific site along a chromosome. The markers may vary among
individuals. Geneticists use the markers as references to determine patterns of genetic variations. See id. at 557t.
12
Id. at 506.
13
Id. at 505, 616.
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Id.
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Id. at 506.
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from the probe increases, it indicates a successful amplification.20 However, even with multiple
PCR amplification cycles, next-generation sequencing continues to be the preferred method of
genetic analysis because it can detect all variants and mutations.
3. Next-Generation Sequencing (“NGS”)
Genotyping deals with differences in an individual’s genetic makeup compared to another
individual and looks at genetic variation among populations.21 Whole-exome and whole-genome
sequencing (next-generation sequencing) involves sequencing the individual’s entire DNA as
opposed to a gene of interest in PCR testing. Whole-exome sequencing examines the exons within
the gene.22 Exons are a portion of the genome that provides instructions for making proteins.23
Whole-exome sequencing identifies variations in the protein-coding region of any gene, which is
efficient in identifying possible disease-causing mutations.24 However, whole-exome sequencing
misses DNA variations that occur outside the exons but still affect gene activity.25 Whole-genome
sequencing can detect differences in any part of the genome and determines the order of all the
nucleotides in an individual’s DNA.26
4. Single Nucleotide Polymorphisms (“SNPs”)
An even cheaper approach to DNA sequencing is to examine SNPs. A SNP is a site in the
genome where one of the nucleotide bases (A, T, G, or C) occurs in several different forms among
different individuals.27 The common sites on the genome are used in the mapping of genes and

20

Id.
Id.
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DEP’T. OF HEALTH & HUMAN SERVS. NAT’L INST. OF HEALTH, NAT’L CTR. FOR BIOMEDICAL
COMMC’N, HELP ME UNDERSTAND GENETICS: GENETIC TESTING (2019), https://ghr.nlm.nih.gov/
[hereinafter Genetic Testing].
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Genetic Testing, supra note 22, § Next-Generation Sequencing.
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Id.
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Id.
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Id.
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Genetic Analysis, supra note 2, at 557t.
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disease-causing alleles during genetic testing as they involve a large number of variations.28
Scientists use SNPs to estimate a person’s ethnic background for ancestry tests and have identified
more than one million SNPs, which correspond to clinical and non-clinical traits.29
B. What is a Direct-to-Consumer (“DTC”) Genetic Test?
DTC genetic testing provides individuals with direct access to their genetic information
without involving a healthcare provider or insurance company. Individuals can buy the tests online
or in stores and submit a DNA sample to the company by mail.30 Customers receive their results
directly from a secure website or in a written report.31 There are various kinds of DTC-GTs
available: ancestry or genealogy, disease risk and health, kinship, and lifestyle.32
1. Genetic Ancestry Testing
Genetic ancestry testing or genealogy testing uses DNA variations from SNPs to provide
an estimate of ethnic background.33 Genetic modification is often shared between people from
similar backgrounds.

34

Genealogy tests can be used in population genetics to study how people

migrated and mixed with other ethnic groups.35 However, ancestry tests are limited because test
results are compared to different databases to identify shared molecular markers.36

28

Id.
Genetic Testing, supra note 22, § DTC Overview; see generally Alain Vignal et al., A Review on SNP and Other
Types of Molecular Markers and Their Use in Animal Genetics, 34 GENETICS SELECTION EVOLUTION 275,
277-78 (2002).
30
Genetic Testing, supra note 22, § DTC Overview.
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Id.
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Id.
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2. Disease Risk and Health
Disease risk and health-based genetic tests estimate an individual’s genetic risk of
developing common diseases/disorders.37 These tests may also identify if an individual is a gene
carrier for a specific genetic variation/mutation.38 A genetic carrier inherits a recessive39 allele for
the genetic trait/mutation but does not display the symptoms of the disease or trait. 40 Carriers can
pass the recessive allele on to their offspring, and if the offspring acquires another recessive allele
from the other parent, the offspring will express the genetic trait/mutation and its symptoms.41
Lifestyle tests are a form of disease risk and health-based tests as they inform the consumer
how DNA variations may impact lifestyle factors, e.g., fitness, weight loss, nutrition, and sleep.42
Results are based on an analysis of genetic mutations “that are known or suspected to be associated
with the disease or trait.”43
C. Direct-to-Consumer Genetic Testing Companies
Direct-to-consumer genetic testing companies (“DTC-GTC’s”) gained prominence with
the sequencing of the human genome. These companies provide genome sequencing services
directly to the consumer. DTC genetic testing currently has very little regulation or oversight.44

37

Id.
Id.
39
“Variant masked by the presence of dominant traits but reappears in subsequent generations.” See Genetic Analysis,
supra note 2, at 23.
40
Id. at 31-2.
41
Id.
42
Id.
43
Genetic Testing, supra note 22, § DTC Overview.
44
James W. Hazel et al., Who Knows What, and When?: A Survey of the Privacy Policies Proffered by U.S. Directto-Consumer Genetic Testing Companies, 28 CORNELL J. OF LAW AND PUB. POL’Y 35, 48-50 (2018).
38
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1. Overview of Companies’ Policies
The majority of genetic testing companies have privacy policies or terms of services
accessible on their websites.45 However, some of these policies only apply to the use of the
company’s website and not the specific test kit and genetic information.46 Some companies only
provide additional consent requirements for participation in third-party research.47 Out of thirty
companies' marketing test kits, most companies failed to “consistently meet international
transparency guidelines related to confidentiality, privacy, and secondary use of data.”48
2. Companies’ use of Genetic Data
Genetic testing companies sometimes share information with pharmaceutical companies.
For instance, 23andMe sells customers’ genetic data to GlaxoSmithKline to translate genetic and
phenotypic data into targeted pharmaceutical treatments for Parkinson’s disease.49 Other
companies share customer data only on an opt-in basis.50 More than 75 percent of customers agree
to participate in the sharing of their data for research in determining disease risk.51 Although most
testing companies only share de-identified data after receiving explicit consent from the consumer,
some websites allow people to upload genetic information and search for relatives.52

45

Id.
Id.
47
Id.
48
Linnea I. Laestadius et al., All Your Data (Effectively) Belong to Us: Data Practices Among Direct-to-Consumer
Genetic Testing Firms, 19 GENETICS IN MED. 513, 513 (2017).
49
Press Release, GlaxoSmithKline, GSK and 23andMe Sign Agreement to Leverage Genetic Insights for the
Development of Novel Medicines (July 25, 2018) https://www.gsk.com/en-gb/media/press-releases/gsk-and23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/. [hereinafter GSK].
50
Julian Segert, UNDERSTANDING OWNERSHIP AND PRIVACY OF GENETIC DATA, Harvard University The
Graduate School of Arts and Sciences (2018) http://sitn.hms.harvard.edu/flash/2018/understanding-ownershipprivacy-genetic-data/.
51
Id.
52
Id.
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GEDMatch’s public upload websites helped law enforcement solve the Golden State Killer
cold case.53 Following the Golden State Killer identification, GEDMatch updated its privacy
policy to state that genetic data from GEDMatch could be freely used by law enforcement.54
Conversely, 23andMe and Ancestry require court orders or valid search warrants before
giving third parties or law enforcement access to genetic data records.55 However, these policies
do not guarantee relatives of the individual any protection from future lawful use. As mentioned
above in ancestry testing, family members share portions of their genome. So even though the
relative does not upload or consent for their genetic information to be shared and utilized, their
heritage can still be identified as well as the possibility of identifying disease risk. With the nature
of the human genome being individually unique, de-identified information may still allow people
to connect the data back to the original person.56
III.

Genetic Testing Privacy Frameworks
Genetic privacy may be compromised if testing companies remain unregulated and use

genetic information in an unauthorized way. Federal and State governments’ privacy laws

53

Linnea M Baudhuin et al, Privacy In Direct-To-Consumer Genetic Testing, 65 CLINICAL CHEMISTRY 612, 61217 (2019) (The police were unable to detect a match through CODIS, so they turned to GEDMatch, a database of
genetic information from approximately 900,000 users who have voluntarily uploaded their genetic data after being
tested by DTC-GTCs. Through GEDMatch, police were able to trace the serial killer to his great-great-great
grandparents and then months later were able to find a branch of the family tree that hailed from the western United
States.)
54
Id.
55
Id.
56
Id. DTC genetic testing consumers need to realize that publicly sharing their data allows anyone access to their
genetic data, and, by default, they place their family members at privacy risk as well. Consumers assume they will be
anonymous; however, researchers have proven that they can rapidly re-identify DTC genetic consumers based on their
genetic test results. Consumer re-identification can reveal very sensitive medical information about the donor and even
about that person's relatives (particularly if, for example, information about mitochondrial DNA or the Y chromosome
is included). It may also be used to connect the donor or a relative to another known DTC genetic consumer; see also
Yaniv Erlich et al., Identity Inference Of Genomic Data Using Long-Range Familial Searches, 362 SCIENCE 690,
690-94 (2018); see also Muhammad Naveed et al. Privacy in the Genomic Era, 48 ACM COMPUT. SURV. 48 (2015);
see also Erika Check Hayden, The Genome Hacker, 497 NATURE 173 (2013); see generally Zhen Lin et al., Genetics,
Genomic Research & Human Subject Privacy, 305 SCIENCE 183, 183 (2004).
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designed to protect consumers’ right to privacy vary in terms of their breadth and do not extend to
DTC-GTs.57

Likewise, genetic testing

companies’ privacy

policies

range in

their

comprehensiveness of the public’s privacy concerns.58
A. Federal Privacy Laws
1. The Fourth Amendment - Searches of DNA Databases by the Government
The Fourth Amendment protects an individual’s privacy interest from unreasonable
searches and seizures:
“The right of the people to be secure in their persons, houses, papers, and effects
against unreasonable searches and seizures, shall not be violated, and no Warrants
shall issue, but upon probable cause, to be supported by Oath or Affirmation and
particularly describing the place to be searched, and the persons or things to be
seized.”59
In Maryland v. King, the Supreme Court found acceptable genetic searches for individuals
with diminished expectations of privacy.60 A lawful arrest based on probable cause for a “serious”
crime permits the police to collect a DNA sample via a cheek swab for identification purposes
because it is minimally intrusive.61 Conducting a DNA test as part of an arrest procedure does not
violate the Fourth Amendment’s protections because it serves legitimate state interests.62
The Fourth Amendment’s protections against searches and seizures generally do not apply
to genetic information that is voluntarily shared, e.g., with a third party through DTC-GTs. In
United States v. Miller, the Supreme Court ruled that voluntary data sharing negates expectations

JOHN HOPKINS UNIV., GENETICS & PUB. POL’Y CTR, SURVEY OF DIRECT-TO-CONSUMER TESTING
STATUTES AND REGULATIONS (2007) [hereinafter Survey of DTC Statutes and Regulations]; See, e.g., Kayte
Spector-Bagdady & Elizabeth R. Pike, Consuming Genomics: Regulating Direct-to-Consumer Genetic and Genomic
Information, 92 NEB. L. REV. 677, 697 (2014).
58
Id.
59
U.S. CONST. Amend IV.
60
Maryland v. King, 133 S. Ct. 1958 (2013).
61
Id.
62
Id.
57
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of privacy.63 This rule denies Fourth Amendment protections under the circumstances described
above in which DTC genetic test results are openly shared through public upload websites. In these
instances, the government does not need to secure a warrant before searching the site for relevant
genetic information.
2. Health Information Portability and Accountability Act (“HIPAA”)
The HIPAA privacy rule only applies to protected health information of covered entities
and their business associates.64 The privacy rule protects all “individually identifiable health
information” held or transmitted by a covered entity or its business associate, in any form of media,
whether electronic, paper, or oral.65 The privacy rule calls this information “protected health
information” or “PHI.” HIPAA applies to HIPAA covered entities, including a health care
provider, a health plan or a health care clearinghouse.66 Under HIPAA, genetic information is
considered health information, and covered entities are prohibited from using and disclosing
genetic information for underwriting purposes.67 DTC-GTC’s transmit information electronically,
but they are not doctors, clinics, psychologists, dentists, chiropractors, nursing homes, nor
pharmacies. DTC-GTs are not covered under HIPAA. Even though genetic tests contain
individually identifiable health information this type of information is not protected.
Under HIPAA, a business associate is an entity that performs certain functions or activities
on behalf of or provides certain services to, a covered entity that involves the use or disclosure of
individually identifiable health information.68 However, the Act does not consider persons or

63

United States v. Miller, 425 U.S. 435 (1976) (finding defendant had no legitimate expectation of privacy in his bank
records because the bank was a third party to which he disclosed his affairs when he opened his account.)
64
See Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 110-233, 122 Stat. 881 (May 21,
2008) Title I, § 105(a); 42 U.S.C.A. § 1320d-9. [hereinafter HIPAA].
65
Id.
66
Id
67
Id.
68
Id.
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organizations business associates if their functions or services do not involve the use or disclosure
of protected health information.69 DTC-GTC’s are not business associates because they do not
perform functions or activities on behalf of a covered entity. However, if the company is providing
services on behalf of a physician, the tests are not DTCs but instead physician-ordered genetic
tests and subject to HIPAA.
3. Genetic Information Nondiscrimination Act (“GINA”)
President Bush signed into law the Genetic Information Nondiscrimination Act on May 21,
2008.70 Under GINA, genetic information is defined as “any individual, information about (1) such
individual’s genetic tests, (2) the genetic tests of family members of such individual, and (3) the
manifestation of a disease or disorder in family members of such individual.”71 GINA is notable
in that it prohibits health insurers from engaging in genetic discrimination and regulates the release
of genetic information and employer’s requirement of genetic testing.72 GINA prevents health
insurers from increasing premiums or denying coverage to individuals based on genetic
information.73 However, GINA does not apply to life, disability, or long-term care insurance.74 If
DTC-GTC’s choose, they can release test results to insurers not covered under GINA upon their
request.75 GINA also does not apply to law enforcement’s use of DTC genetic data.76

69

Id.
See Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff (2008) [hereinafter GINA].
71
Id.
72
78 Fed. Reg 5658 (January 25, 2013).
73
Id.
74
Id.
75
Id.
76
Id.
70
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4. Food and Drug Administration (“FDA”)
The FDA classifies DTC-GTs as lower-risk medical devices subjected to the FDA’s
“regulatory purview.”77 Currently, the FDA regulates a test kit based on how it comes to the
market, i.e., a commercial test kit or a laboratory-developed test (LDT).78 On the one hand, a
commercial marketed test kit processes genetic samples packaged together and sold to multiple
laboratories.79 On the other hand, an LDT test kit is developed, performed, and sent to a single
laboratory.80 The FDA chooses not to regulate LDTs for clinical or analytical validity because
physicians order the tests.81
Generally, the FDA does not review DTC tests for non-medical, low-risk medical, or
general wellness purposes.82 The FDA evaluates moderate and high-risk tests before they can be
offered to individuals to assess the tests' analytical and clinical validity.83 Carrier screening tests
that determine whether an individual carries a genetic variant that can be passed down to offspring
are exempt from FDA premarket review.84 Genetic tests intended to provide information about

NAT’L INST. OF HEALTH, NAT’L HUMAN GENOME INST., REGULATION OF GENETIC TESTS (2018)
genome.gov/about-genomics/policy-issues/Regulation-of-Genetic-Tests. [hereinafter Regulation of Genetic Tests].
78
Id.
79
Id.
80
Id.
81
Id.
82
FOOD & DRUG ADMIN. DIRECT-TO-CONSUMER TESTS, MEDICAL DEVICES: IN VITRO
DIAGNOSTICS https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests.
83
Id.; The FDA authorized 23andMe to offer a direct-to-consumer carrier status test for Bloom Syndrome in February
2015, subsequently authorized it to carry out Genetic Health Risk (GHR) tests for ten diseases in April 2017, and
mostly recently, authorized a test that reports on three mutations in BRCA genes in March 2018. As part of the premarket approval process for GHR tests, 23andMe was required to demonstrate the analytical validity of their tests as
well as adequate consumer understanding of the sample collection process and the resulting genetic reports. Going
forward, the FDA “intends to exempt additional 23andMe GHR tests from the FDA’s premarket review, and GHR
tests from other makers may be exempt after submitting their first premarket notification . . . allow[ing] other, similar
tests to enter the market as quickly as possible and in the least burdensome way, after a one-time FDA review.” Press
Release, Fed. Drug Admin., FDA Allows Marketing of First Direct-to-Consumer Tests that Provide Genetic Risk
Information for Certain Conditions (April 6, 2017), https://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm551185.htm; See also Press Release, Fed. Drug. Admin., FDA Permits Marketing of First
Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome (Feb. 23, 2015), https://www.fda
.gov/newsevents/newsroom/pressannouncements/ucm435003.htm.
84
21 CFR 866.5940.
77
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specific medical conditions or diseases, and tests designed to provide information explaining
medication side effects and genetic interaction are required to obtain FDA clearance before DTCGTCs can offer the tests.85
5. Clinical Laboratory Improvement Act (“CLIA”)
The FDA and the Centers for Medicare and Medicaid Services (“CMS”) have the authority
to regulate genetic tests.86 However, CMS regulation only extends to the analytical validity87 of
the tests, not to the protection of individual private information.88 CMS regulates clinical
laboratories through CLIA, which establishes a certification process for laboratories to process
medical samples.89 While CLIA determines clinical testing quality, including verifying the
procedures used, it does not examine whether tests are clinically valid or whether safeguards are
in place to protect individual privacy.90
Laboratories' compliance with CLIA depends on the nature and complexity of the tests
performed. CLIA classifies most genetic tests as moderate or high-complexity laboratory tests.91
Laboratories that only perform tests that are simple laboratory examinations and procedures that
pose no reasonable risk of harm if performed incorrectly may qualify for a certificate of waiver.92
Moderate and high-complexity tests require a certificate of compliance by CMS.93 Laboratories

85

21 CFR 866.5950; 21 CFR 862.3364.
Regulation of Genetic Tests, supra note 77.
87
Id. Analytical validity refers to how well the test predicts a genetic change.
88
Id.
89
Id.
90
Id.
91
NAT’L INST. OF HEALTH, NAT’L HUMAN GENOME INST., THE CLIA FRAMEWORK, (2018)
https://www.genome.gov/Pages/PolicyEthics/GeneticTesting/The_CLIA_Framework.pdf.
[hereinafter
CLIA
Framework].
92
42 CFR 493.15.
93
CLIA Framework, supra note 91.
86
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that perform genetic tests have the option to either go through a proficiency testing program or
evaluate their testing programs at least twice a year.94
Clinical laboratories that comply with CLIA may release information “for the diagnosis,
prevention, or treatment of any disease or impairment of, or the assessment of the health of, human
beings.”95 Laboratories are exempt from CLIA requirements if they are “research laboratories that
test human specimens but do not report patient-specific results for the diagnosis, prevention or
treatment of any disease or impairment of, or the assessment of the health of individual patients.”96
Here, DTC-GTCs do not need to comply with CLIA because they communicate test results
to consumers, not for the diagnosis, prevention, or treatment of any disease or impairment. DTCGTCs purpose is for consumers to obtain information related to ancestry, risk of disease, and nonclinical traits (hair color, earlobe type). LDTs, as discussed above, would need to comply with
CLIA requirements as they are moderate or high complexity tests.
6. Federal Trade Commission (“FTC”) Privacy Protection Laws
The FTC recommends that consumers scrutinize the company’s website and privacy
practices regarding how genomic data is used, stored, and disclosed before buying a test kit.97
Although the FTC does not provide genetic privacy protection, it can take action against companies
that do not safeguard consumers' personal data.98 The FTC also has broad authority to police unfair

94

CLIA Framework, supra note 91. See also 42 CFR 493.801(2)(ii).
42 U.S.C. 263a.
96
42 CFR 493.3(2).
97
U.S. FED. TRADE COMM’N, DIRECT-TO-CONSUMER GENETIC TESTS, (2018); See also U.S. FED. TRADE
COMM’N, DNA TEST KITS: CONSIDER THE PRIVACY IMPLICATIONS, (2017).
98
See generally LabMD v. FTC, 1:14-cv-00810-WSD (11th Cir. 2019) (LabMD engaged in unreasonable data security
practices that resulted in the unauthorized sharing of sensitive medical information. FTC concluded privacy harm is a
substantial injury to consumers and LabMD must establish a comprehensive information security program subject to
assessments); see also Press Release, U.S. Fed. Trade Comm’n, FTC Announces Settlements with Four Companies
Related to Allegations they Deceived Consumers over Participation in the EU-Privacy Shield, (Dec. 3, 2019)
https://www.ftc.gov/news-events/press-releases/2019/12/ftc-announces-settlements-four-companies-relatedallegations-they.
95
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and deceptive practices under the FTC Act.99 The only meaningful action the FTC took was against
GeneLink in 2014 for health-related claims not supported by the evidence, and data security
practices that rose to the level of unfair and deceptive.100 The Health Breach Notification Rule
requires businesses not covered by HIPAA to notify customers if there is a breach of “unsecured,
individually identifiable electronic health information.”101 The rule applies to a vendor of personal
health records who maintains an online service that allows consumers to share, organize, and
manage identifiable health information drawn from multiple sources e.g. maintaining medical
records in a physician’s mobile application to upload changes in weight, blood pressure, and
diet.102
DTC-GTCs will be subject to the FTC’s oversight regarding compliance with the EUPrivacy Shield and data security practices. However, the health breach notification rule does not
apply to DTC-GTCs because they are not a vendor, i.e., they do not maintain a service for patients
to access and upload changes to medical records.
7. Common Rule for Clinical Research
The Common Rule mandates that research involving FDA-regulated products or research
conducted or supported by a federal agency must seek Institutional Review Board (“IRB”)
approval before conducting studies involving human subjects.103 Research projects limited to

Fed. Trade Comm’n Act of 1914 15 U.S.C. §§41-58 (2018).
In Re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095 U.S. Fed. Trade Comm’n (Jan. 7, 2014).
101
Health Breach Notification Rule, U.S. Fed. Trade Comm’n.
102
Id.
103
Ernest D. Prentice & Bruce G. Gordon, Institutional Review Board Assessment of Risks and Benefits Associated
with Research, 2 NAT’L BIOETHICS ADVISORY COMM’N, ETHICAL & POL’Y ISSUES IN RESEARCH
INVOLVING HUMAN PARTICIPANTS, 1 (2001).
99

100
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publicly available data are not subject to IRB review.104 Researchers do not need prior IRB
approval for aggregated and de-identified genetic information.105
DTC-GTCs have added research opportunities where customers can share their genetic
information for use in research (23andWe, and Navigenics).106 23andMe’s research division,
called 23andWe, is structured to investigate the causes of diseases and develops drugs and
treatments accordingly.107 23andWe incorporates a large pool of samples from consumers
participating in standard test kits and establishes location-based clinical trials.108 Research
participants of the clinical trials contribute their genetic information and health background
prompted by online surveys.109 Other DTC-GTCs like Navigenics “believe in … helping further
scientific and medical research.”110 The company may use consumers' genetic data to “discover
and validate associations between certain genetic variations and certain health conditions or
traits.”111 Navigenics findings may be published “without disclosing Genetic Data sufficient to
uniquely identify [participants].”112 deCODEme also invites its customers to participate in research
activities.113 Private-based DTC-GTCs are not required to seek IRB approval for research projects
as they do not receive federal funding and are not subject to federal regulations.

104

45 CFR 46.102(b)(4).
45 CFR 46.102(f) biological specimens or private information is identifiable when it can be linked directly or
indirectly to a specific individual, when this information is obtained for research purposes it constitutes as human
subjects research. See also U.S. DEPT. OF HEALTH AND HUMAN SERVICES, OFFICE FOR HUMAN
RESEARCH PROTECTIONS, GUIDANCE ON CODED PRIVATE INFORMATION OR SPECIMENS USE IN
RESEARCH, (2008) https://www.hhs.gov/ohrp/regulations-and-policy/guidance/research-involving-coded-privateinformation/index.html.
106
45 CFR 46.102(b)(4).
107
Consent Document, 23andMe, https://www.23andme.com/about/consent.
108
Research Revolution, 23andMe, https://www.23andme.com/researchrevolution.
109
Consent Document, supra note 107.
110
Privacy Policy, Navigenics, http://www.navigenics.com/visitor/what_we_offer/our_policies/privacy.
111
Id.
112
Id.
113
Terms of Use, deCODEme, http://decodeme.com/terms-of-use.
105

Missel 16

B. State Privacy Laws
Most states have enacted legislation to prohibit insurers from collecting or using genetic
information to discriminate.114
1. California Consumer Privacy Act (“CCPA”)
The CCPA provides California residents with the right to (1) know what personal data115
is collected about them; (2) be notified of sale or disclosure of personal data; (3) object to the sale
of personal data; (4) access their data; (5) freedom to exercise their rights without fear of
discrimination; and (6) request a business to delete any acquired personal data. 116 CCPA applies
to any organization that does business in California and has either (1) annual gross revenues greater
than $25 million; (2) earns more than half of its revenue from selling consumers' personal
information or (3) maintains the personal information of 50,000 or more consumers.117
Corporations are required to (1) designate methods for submitting data access requests; 118 (2)
update privacy policies to include a description of residents’ rights;119 and (3) the company’s
website must have an opt-out link on the homepage to “Do Not Sell My Personal Information.”120
Companies who do not comply may be fined up to $7,500 for each intentional violation, $2,500

NAT’L CONFERENCE OF STATE LEGISLATORS, STATE GENETIC PRIVACY LAWS,
http://www.ncsl.org/research/health/genetic-nondiscrimination-in-healht-insurance-laws.aspx [hereinafter State
Privacy Laws].
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for each unintentional violation, and statutory damages between $100-$750 per California resident
if they become victims of data theft or breach.121
23andMe is subjected to CCPA because it maintains personal information, including
biometric data of more than 50,000 consumers, has annual gross revenue over $25 million, and
conducts business in California.122 Because not every aspect of 23andMe’s business takes place
outside of California, CCPA restricts the business’ ability to collect or sell consumers’ personal
information. Anything de-identified or aggregated under CCPA is not considered publicly
available and is subject to the Act's compliance.
2. Other State Laws and Regulations
States’ privacy protections vary.123 Some states mandate individual access to personal
genetic information.124 Genetic information is defined as “personal property” in Alaska, Colorado,
Florida, Georgia, and Louisiana.125 Likewise, Rhode Island and Washington require companies to
receive written authorization to disclose genetic information.126 Forty-seven states prohibit the use
of genetic information to determine rates of insurance eligibility.127 Twenty-seven states require
informed consent for a third party to perform or request a genetic test or to obtain genetic
information.128 Eighteen states have specific penalties for violating genetic privacy laws.129 One
state extends personal property rights to DNA samples.130
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C. International Transparency Standards – General Data Protection Regulation
In May 2018, the European Union (“EU”) launched the General Data Protection Regulation
(“GDPR”) to protect the “fundamental rights and freedoms of natural persons and their right to the
protection of personal data.”131 GDPR applies to all companies, not just healthcare providers or
insurance companies. GDPR defines personal health data to include:
“all data pertaining to the health status of a data subject which reveal information
relating to the past, current or future physical or mental health status of the data
subject. This includes information about the natural person collected in the course
of the registration form, or the provision of, health care services as…a number,
symbol or particular assigned to a natural person to uniquely identify the natural
person for health purposes; information derived from the testing or examination of
a body part or bodily substance, including from Genetic Data and biological
samples; and any information on, for example, a disease, disability, disease risk,
medical history, clinical treatment or the physiological or biomedical state of the
data subject independent of its source, from a physician or other health professional,
a hospital, a medical device or an in vitro diagnostic test.”132
GDPR is legally binding for United States businesses with global operations, international
sites, or even remote workers.133 The GDPR defines genetic data as personal data
“relating to the inherited or acquired genetic characteristics of a natural person
which result from the analysis of a biological sample from the natural person in
question, in particular chromosomal, deoxyribonucleic acid (DNA) or ribonucleic
acid (RNA) analysis, or from the analysis of another element enabling equivalent
information to be obtained.”134
Any test results acquired from DTC-GTs create genetic data, and as such, any testing companies
that function in the EU must adhere to GDPR for personal data and consent. Under GDPR,
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processing of personal data requires approval from the data subject or an expressed provision of
law.135 GDPR also requires the right of EU citizens to be informed about the storage and use of
their data.136 A company must immediately notify individuals when obtaining their data.137
Companies like 23andMe and Ancestry that are global companies offering consumer health
services would be considered controllers under the GDPR. As a controller, these testing companies
are responsible for maintaining the protection of personal data through consent and processing
requirements.
D. Future of Privacy Forum Best Practices
The Future of Privacy Forum established voluntary privacy best practices for consumer
genetic testing services.138 Companies’ privacy practices are required to maintain complete
transparency about how genetic data is collected, used, shared, and retained. 139 The privacy
disclosure must include publicly posting a high-level summary of privacy protections easily
accessible to consumers.140 Companies must have a separate express consent for the transfer of
genetic information to third parties and are banned from sharing the information with employers,
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Recital 32 Conditions for Consent, General Data Protection Regulation; See also Art 7. GDPR Conditions for
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insurance companies, educational institutions, and government agencies without consent unless
required by law.141 However, DTC-GTCs are not required to participate in the future of privacy
forum, and only a select number of companies are supporters of the best practices, including
23andMe, Ancestry, MyHeritage, Helix, Habit, African Ancestry, and Living DNA.142 If a
company’s policy conflicts with the best practices, the forum will remove the company as a
supporter.143
E. Genetic Testing Companies’ Privacy Policies
Both 23andMe and Ancestry present customers with two documents upon purchasing a test
kit. The first document the companies present are the terms and conditions that include a privacy
statement. The second document is an informed consent document. Customers must accept the
terms and conditions before they can buy a test kit from the company. The informed consent
document is presented to consumers when they are registering their test kit as it relates to additional
research projects run by the company, e.g., 23andWe. Both 23andMe and Ancestry have a history
of sharing anonymized consumer data with third parties.
1. 23andMe
23andMe’s website contains very detailed privacy statements, which address how the
company collects, manipulates, and protects genetic information.144 The website defines personal
information as “information that can be used to identify a user either alone or in combination with
other information.”145 Personal information is broken down into genetic information (data
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generated by processing a user’s DNA sample), registration information (name, email address, etc.
used to create an account or purchase test kits), and self-reported information (user’s response to
surveys).146
23andMe requires users to complete two informed consent documents.147 The main
research consent document includes that 23andMe can use individual-level genetic information
and self-reported information internally.148 For third party research purposes, the information must
be de-identified and not linked to registration information.149 The company also provides an
individual-level data sharing consent form which includes the same uses as above and that
23andMe may share de-identified individual-level genetic information and self-reported
information with select third party research contributors.150 The document also allows users to
withdraw consent by changing their consent status in their account settings.151 However, once data
is shared with third parties, it will not be withdrawn.152 23andMe also does not state how it protects
the confidentiality of the shared information or how it prohibits attempts to re-identify individuals.
23andMe is also committed to compliance with GDPR.153
23andMe maintains different levels of data sharing.154 Users’ aggregate data, individuallevel genetic information, and self-reported information may be shared as specified in the consent
document.155 23andMe may share with both commercial third parties, and non-profits
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aggregated156 genetic and self-reported data.157 De-identified genetic information may be
published in peer-review journals and other research funded by the federal government (NIH)
conducted by 23andMe.158 23andMe research may be sponsored, conducted on behalf, or in
collaboration with third parties (foundations, academic institutions and pharmaceutical
companies).159
2. Ancestry DNA
Ancestry DNA states customers' genetic data will be used correctly for: “genetic and
genealogical research, including population health and ethnicity-related analyses, and not to
provide you individual medical or diagnostic purposes.”160 Put another way, Ancestry uses genetic
information to provide customers with ancestry results and identify relatives based on similar DNA
molecular markers. The company also states that consumer data is de-identified to make
discoveries in population genetics.161 Ancestry DNA’s privacy policy contains three significant
provisions: “(1) the perpetual, royalty-free, worldwide license to use your DNA; (2) the warning
that DNA information may be used against ‘you or a genetic relative’; and (3) your waiver of legal
rights.”162 These provisions give a written warning to Ancestry customers but are embedded in
“click-wrap” (requiring the user to “agree” upon ordering the kit, which most consumers consent

Privacy Statement, supra note 144. “It has been stripped of registration information and combined with data from
other users to minimize the possibility of exposing individual-level information.” Aggregate data is information
combined with other users and analyzed or evaluated as a whole with no specific individual identified. e.g., 30% of
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genotypes, diseases or other traits/characteristics.
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to without reading the entire agreement) or “browser-wrap” (implies consent by use of the website)
agreements.163 Furthermore, Ancestry maintains ownership of the customers’ DNA in
perpetuity.164
3. Personal Genome Project
Harvard School of Medicine’s Personal Genome Project (“PGP”) publishes all information
submitted by a participant, including physical traits, medical information, and photographs on
PGP’s public website along with genetic information.165 While individuals interested in
participating must submit to a rigorous pre-enrollment questionnaire and consent process, family
members do not.166 Once PGP releases the information, neither PGP nor the participant can control
who has access, can make copies, or use the information.167 This poses a concern for the individual
as well as family members because “anyone with sufficient knowledge and resources” could use
the data to claim a participant is predisposed to a disease, or they are related to criminals.168
4. Burying Privacy Disclaimers in Terms and Conditions
While genetic testing companies claim to have privacy protections surrounding genetic
information, most of the policies follow a take it or leave it approach. If individuals do not consent
to the privacy statements, they cannot obtain a DTC-GT. Consumers consent to collecting risk
information and disclosure of results by clicking “yes” on a dialogue box. The mere click should
not be considered informed consent unless consumers spend the time to read the disclosure in its
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entirety.169 Consenting to terms and conditions by clicking on an “accept” or “yes” dialogue box
is now very commonplace given the bombardment of consumers downloading applications and
routine operating system updates, which most people consent to without reading the statements.170
If customers of DTC-GTs operate reading the permission in the same way that they consent to
system updates, they are genuinely not informed. Companies can bury privacy information, the
length samples will be kept, and means of selling genetic information in the “informed consent”
without customers knowing how their genetic information is being stored and manipulated. The
gaps in privacy regulations cause consumers to agree to security protections absentmindedly and
as routine as clicking through website terms and conditions.
IV.

Gaps in Existing Consumer Protection
Despite the existing federal and state safeguards, some of these laws still do not adequately

address privacy issues and consumer protection related to genomic data. Consumers may believe
that HIPAA protects their information yet, HIPAA does not cover DTC genetic testing companies
as detailed above. Both CLIA and the FDA continue to have a regulatory gap with no oversight to
protect individual privacy when analyzing DTC-GTs. The FTC has done very little to enforce
companies’ privacy compliance. Nevertheless, privacy concerns persist with the sharing of de-
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identified information because, with emerging technology, third parties may misuse this
information and is not truly de-identified.171
A. Potential for Third-Party Misuse of Data
Whole exome and whole-genome sequencing, as mentioned above, rely on sharing data by
looking at the genomic sequences of large populations of people. However, there are concerns that
this technology will affect individual privacy with the increased number of individuals who can
access the data leading to misuse or breach. The misuse or breach of data stems from recent events
involving electronic health record breaches.172
Several state statutes require the preservation of DNA samples.173 Preservation of the
sample allows future testing of the sample when new technologies become available. 174 The
preservation of the sample also raises concerns about physicians’ misuse of consumer health
information.175 However, physicians are HIPAA covered entities and cannot share PHI for
marketing tactics unless they fall into a HIPAA exception.176
Conversely, DTC-GTCs may misuse consumer health information for marketing since
there are no regulatory requirements in place to govern the use of personal data. While physicians
cannot manipulate genetic information, DTC-GTCs are not HIPAA covered entities, and no other
federal or state laws prohibit testing companies' use of genetic information for promotional
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purposes. Testing companies governed by GDPR cannot process, store, or share genetic
information with third parties without the express permission of the individual.
There is also the potential for misuse of data in what is being called “DNA theft.”177 There
is an increased risk that “third parties may attempt to collect and analyze anyone’s DNA without
consent.”178 Since DTC-GTCs only require a customer to accept the company’s terms and
conditions before purchasing a kit, individuals may submit another person’s sample without their
knowledge or consent. Public databases like PGP and GEDMatch could also result in false claims
of a criminal relationship or disease predisposition if someone altered and republished the same
data obtained from DTC-GTCs. Someone could also make synthetic DNA from the public
database and plant it at a crime scene to implicate a person in a crime.
B. Using Molecular Markers to De-Anonymize Genetic Data
The nature of genetics is information taken from one person’s genetic composition that
may be shared with biological siblings and offspring.179 For this reason, genetic information is
considered sensitive, primarily since it can also determine predisposition to a gene that could affect
an individual or a family.180 Genetic data can be de-anonymized by genetic markers tied to specific
physical traits like hair and eye color.181 The physical characteristics can be cross-referenced with
publicly available data to identify whom the DNA belongs to.182
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People believe a “robust anonymization assumption” that by removing specific identifiers,
the individual would remain anonymous.183 The NIH removed some genetic data from publicly
available websites184 following a study that identified a single individual’s DNA contribution from
a pool of a thousand samples.185 Another example deals with the Massachusetts Group Insurance
Commission’s removal of explicit identifiers where researchers were able to de-identify patient
records and identify the governor.186 As previously discussed, SNPs are useful in DTC-GTs
because they correspond to both non-clinical and clinical traits. A study in 2004 determined that
thirty SNPs can be used to identify a single person out of the millions of SNPs analyzed in a genetic
test.187 Someone who has access to both anonymized genetic data and public data may be able to
de-anonymize the data and identify an individual with a small set of SNPs. Scientists can also
determine a person’s surname by studying the short tandem repeats on the Y chromosome and
linking that with publicly available information.188
Any form of genetic information sharing through the public domain or for research (DTCGTCs information sharing with third-parties and non-profit research institutions) creates the
possibility that someone will access the data and re-identify the set. As mentioned in PGP’s
overview, this poses a concern for the individual as well as family members. The gaps in protection
implicate autonomy and privacy for family members who do not want to share their genetic
information or know risk facts that their relatives’ DNA might reveal.
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C. Access to Genetic Information by Life, Disability, and Long-Term Care Insurance
The dangers of misinterpretation of genetic information attribute to the fears of gene
testing, genetic discrimination, and insurance coverage. For instance, genetic tests could
previously lead to discrimination by insurance companies in terms of health care coverage.189
Though under GINA genetic discrimination is prohibited by corporations and health insurers,
genetic tests also bring about concerns for life, disability, and long-term care insurance
coverage.190
Genetic test results have led to manipulation by life, disability, and long-term care
insurance companies. Companies that offer these policies have the right to request genetic test
results when making decisions about coverage and insurance premiums.191 Insurance companies
then use this information to place people into groups based on risks. Specifically, if a genetic test
was shown as part of the patient’s medical history, insurance companies could use this information
to determine coverage for life and disability insurance.
Nevertheless, just because someone has a predisposition to something, there is no
guarantee they will manifest the disease during their insurance period. If the individual did not
disclose the test results, they would be evaluated as less risky and have slightly better premiums.
Additionally, physicians include genetic results from tests they order into the patient’s medical
record, and the insurance company will most likely have access to that information. Given the
consent forms DTC-GTCs require consumers to submit for research purposes, DTC-GT results
hopefully are secure from the insurance companies' access. Due to genetic discrimination in these
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types of insurance, people may avoid genetic tests for fear that taking the test or getting a positive
result could affect their coverage.
V.

Consideration of Mechanisms to Maintain Individual Privacy
The United States needs new genetic privacy laws to protect individual privacy, related

explicitly to DTC-GTs. Providing privacy protections should be maintained on a federal level, not
on a state-by-state basis. State-based privacy protections would not solve consumers’ privacy
concerns, as some states may allow sharing of genetic information that could link a family member
who does not want their information shared from a state with more stringent privacy protections.
The federal government should focus on either applying a standard like GDPR or modify what is
classified as a HIPAA covered entity. The main difference between the structure of GDPR and
HIPAA is that GDPR defines entities based on ownership of data, and HIPAA defines entities
based on the function of the organization.
A. Expansion of HIPAA and GINA
Congress should amend HIPAA to include genetic testing companies as covered entities
under HIPAA. Most consumers assume their genetic information is stored and protected following
HIPAA regulations. However, as discussed above, that is not the case. HIPAA does not govern
the activities of genetic testing companies because they are not considered covered entities or
business associates. Consumers must then agree to privacy and security protections through clickthrough policies. If genetic testing companies were classified as covered entities, because they
already transmit information in an electronic form, they could not share consumers’ genetic
information. A criticism to this approach, is that by preventing information sharing it halts
scientific growth and expansion. Anonymized consumer genetic information may be helpful in
identifying diseases or genetic irregularities in various communities through population genetics
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as researchers can have access to large sample sizes. However, the drawbacks to expanding HIPAA
do not outweigh protecting consumer privacy interests, as individuals can still elect to have DTCGTCs sell their data.
Congress should also expand GINA to include protection of all genetic data regardless of
the source of that information. In conjunction with the HIPAA expansion, this would help to
ameliorate some of the effects of data misuse and insurance discrimination while boosting
consumer participation in buying test kits. The FDA and CLIA could also regulate DTC-GTC’s
commercial test kits in the same manner that they regulate LDTs ordered by physicians. The
proposed changes would fill in some gaps, but it would not prevent re-identification from public
domain uploads.
B. Protection Against Re-identification and Restricting Research
A primary unintended consequence of data sharing, DTC-GTs, and genetic research is the
misuse of data and de-anonymization. Congress could expand the Common Rule to include all
research projects, whether implemented by private companies or those under federal
grants/regulations. Then DTC-GTCs would have to draft research proposals and consent
documents for IRB approval before sharing genetic information with third parties and
pharmaceutical companies. However, DTC-GTCs are unlikely to support this change because it
may prevent research opportunities and minimize the profit DTC-GTCs can receive for selling
genetic data to pharmaceutical companies.
Another solution is to have consumers maintain ownership of their data. In turn, genetic
testing companies would provide customers with a complete readout of their genome that the
individual could anonymously share with whomever at their choosing, including third-party
pharmaceutical companies interested in marketing drugs to individuals based on genetic markers.
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This structure is like GDPR right to data portability in which subjects have the right to receive and
transmit their data with whom they see fit without any hindrance.192 However, this may also lead
to re-identification if the information ends up in the wrong hands. Furthermore, data portability
requirements would be inapplicable to PGP’s structure because one of its goals is unrestricted,
public sharing.
C. GDPR-like Regulatory Framework
The best approach is to apply a federal privacy standard similar to how the EU structured
the GDPR by requiring notification of when personal data is obtained and how the records are
processed. GDPR processing requirements would still allow the federal government to access
personal data relating to criminal convictions or offenses.193 The GDPR fines194 also provide
companies incentives to maintain compliance with the regulations. Researchers that share
biological samples that contain genetic information would be held to personal data protection
standards. This approach would require researchers to notify individuals when biological samples
are processed and obtain express consent from the individuals before processing information and
sharing it with third parties. The GDPR also requires data to be destroyed once the relationship
between the controller and the processor ends. By implying this requirement, it limits the ability
to aggregate and retain personal data for future use, which in turn can prevent the potential for
third-party misuse of data and reduce/eliminate de-anonymizing genetic data. While this may not
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Art. 20 GDPR Right to Data Portability.
Art. 10 GDPR Processing of personal data relating to criminal convictions and offences. Processing of personal
data relating to criminal convictions and offences or related security measures based on Article 6(1) shall be carried
out only under the control of official authority or when the processing is authorized by Union or Member State law
providing for appropriate safeguards for the rights and freedoms of data subjects. Any comprehensive register of
criminal convictions shall be kept only under the control of official authority.
194
If a company does not maintain records of processing activities and/or does not provide a complete index to
authorities, they are subject to fines according to Art. 83(4)(a) of the GDPR. The possible fines can be up to 10 million
euros or 4% of their annual turnover. This total is, as a rule, only assessed by the authorities in exceptional cases. For
this, the authorities are encouraged, as set forth in recital 13, “to take account of the specific needs of micro, small and
medium-sized enterprises in the application of this Regulation.”
193
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be a perfect solution, it gives consumers more control over their personal information even though
it may dissuade companies from selling or utilizing consumers’ data.
VI.

Conclusion
DTC-GTC’s need to implement robust privacy and security programs to mitigate the gaps

in regulation with improved data storing and sharing security. Currently, there are no precise
regulatory mechanisms in place to protect patient autonomy and individual privacy. Because so
much can be gained from DTC-GTs and genetic research, participation should be protected where
possible. At a minimum, Congress should expand HIPAA and GINA to cover all genetic
information no matter where the data is obtained. Nevertheless, the best approach is to enact a
GDPR-like regulatory framework that would promote individual autonomy and privacy while
fostering a collaborative research environment.
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